FLT3L-secreting cDC1 in situ vaccination enhances antitumor immunity and synergizes with PD-1 blockade in murine non-small cell lung cancer

By afschroeder • June 26, 2026

Abascal J, Dumitras C, Tran LM, Crosson W, Kahangi B, Oh M, Rennels A, Lim RJ, Jiang H, Reyimjan D, Coleman NJ, Perez-Reyes E, Chin S, Krysan K, Dubinett SM, Liu B, Salehi-Rad R. FLT3L-secreting cDC1 in situ vaccination enhances antitumor immunity and synergizes with PD-1 blockade in murine non-small cell lung cancer. J Immunother Cancer. 2026 Jun 25;14(6):e014914. doi: 10.1136/jitc-2026-014914. PMID: 42350046.

Tags: Dendritic, Hematology/Oncology, immunotherapy, Lung cancer, Publications, Pulmonary, Critical Care & Sleep Medicine, vaccine, Veterans Administration

Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study

Rini BI, Choueiri TK, Voss MH, Burotto M, Oldenburg J, Gurney HP, Ferguson TR, Hammers H, Albiges L, Ürün Y, Romero Diaz RI, Özgüroğlu M,[...]

Systemic Mastocytosis With Associated Acute Myeloid Leukemia Identified After Induction Therapy: A Case Report and Literature Review

Han J, Ghamsari F, Yan J, Kim P. Systemic Mastocytosis With Associated Acute Myeloid Leukemia Identified After Induction Therapy: A Case Report and Literature Review.[...]

Efficacy and toxicity of antibody-drug conjugates in older adults with breast cancer: A systematic review and meta-analysis

Margolis S, Kalbasi TR, Zektser Y, Niknafs A, Cui J, Lipsyc-Sharf MD, LeVee AA, Rugo HS, Bardia A, Sedrak MS. Efficacy and toxicity of antibody-drug[...]